Bullish option flow detected in Crispr Therapeutics (CRSP) with 2,899 calls trading, 1.4x expected, and implied vol increasing almost 2 points to 61.27%. Jun-25 30 calls and Oct-25 40 calls are the most active options, with total volume in those strikes near 910 contracts. The Put/Call Ratio is 0.14. Earnings are expected on August 5th.

Confident Investing Starts Here:

Easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CRSP:

Disclaimer & DisclosureReport an Issue

Strategic Growth and De-risking: Gil Blum’s Buy Rating on Crispr Therapeutics AG Promising Potential of Crispr Therapeutics AG: Buy Rating Backed by Strategic Partnership and Diversified Pipeline Crispr Therapeutics AG: Strategic Advancements and Growth Potential Drive Buy Rating Buy Rating for CRISPR Therapeutics: Strategic Collaboration with Sirius Therapeutics to Enhance Pipeline and Capture Anticoagulant Market Share Strategic Expansion and Promising Ventures Drive Buy Rating for Crispr Therapeutics AG

View Comments